Your browser doesn't support javascript.
loading
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Viale, G; Regan, M M; Dell'Orto, P; Mastropasqua, M G; Maiorano, E; Rasmussen, B B; MacGrogan, G; Forbes, J F; Paridaens, R J; Colleoni, M; Láng, I; Thürlimann, B; Mouridsen, H; Mauriac, L; Gelber, R D; Price, K N; Goldhirsch, A; Gusterson, B A; Coates, A S.
Affiliation
  • Viale G; International Breast Cancer Study Group Central Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. giuseppe.viale@ieo.it
Ann Oncol ; 22(10): 2201-7, 2011 Oct.
Article in En | MEDLINE | ID: mdl-21335417
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Aromatase Inhibitors Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Aromatase Inhibitors Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: Country of publication: